Alder BioPharmaceuticals, Inc.

Corporate Headquarters
11804 North Creek Parkway South
Bothell
Washington
98011
United States

Tel: 425-205-2900
Fax: 425-205-2901

Email: hr@alderbio.com

Show jobs for this employer

About Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. 

Stock Symbol: ALDR

Stock Exchange: NASDAQ

109 articles with Alder BioPharmaceuticals, Inc.